Literature DB >> 11305577

Combination of signal intensity measurements of lesions in the peripheral zone of prostate with MRI and serum PSA level for differentiating benign disease from prostate cancer.

K Engelhard1, H P Hollenbach, M Deimling, M Kreckel, C Riedl.   

Abstract

The aim of this study was to predict the benign or malignant nature of a prostatic lesion by defining a threshold value of signal intensity ratio and a limiting value of serum prostate-specific antigen (PSA) in patients with elevated PSA level. Twenty-six patients with elevated PSA level and no hypoechogenic lesions at endosonography underwent MR imaging using an endorectal body phased-array coil at 1.5 T (Siemens Magnetom Symphony). A T2-weighted turbo-spin-echo (TSE) pulse sequence was applied in a transverse orientation. Two radiologists evaluated the images. In the presence of a pathological finding they defined regions of interest (ROI) in the suspicious pathological area of the peripheral zone and in muscle for reference. The quotient of the two ROIs was calculated and then correlated with the actual PSA level. Diagnosis was confirmed by prostate biopsy. Ten of 12 patients with quotients smaller than 4 showed cancer at histology. Nine of 12 men with cancer proven by biopsy had PSA levels higher than 10 ng/ml. A significant difference (p < 0.001) was found between the quotients of cancer and quotients of chronic prostatitis, fibrosis, or glandular atrophy. The accuracy of tumor differentiation of the method was 77%. Measurement of signal intensity quotients in the peripheral zone of the prostate in combination with knowledge of defined limits of PSA levels the technique could be helpful in detecting additional cancer areas for prostate biopsy. False-negative tumor results of standard sextant biopsy can be reduced. In men with high PSA values the method has a role in differentiating between patients who require prostate biopsy and those of clinical observation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11305577     DOI: 10.1007/s003300000524

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  10 in total

1.  Dynamic contrast-enhanced MRI of the prostate: is this the way to proceed for characterization of prostatic carcinoma?

Authors:  R H Oyen
Journal:  Eur Radiol       Date:  2003-05       Impact factor: 5.315

Review 2.  Prostate MRI and 3D MR spectroscopy: how we do it.

Authors:  Sadhna Verma; Arumugam Rajesh; Jurgen J Fütterer; Baris Turkbey; Tom W J Scheenen; Yuxi Pang; Peter L Choyke; John Kurhanewicz
Journal:  AJR Am J Roentgenol       Date:  2010-06       Impact factor: 3.959

3.  Prostate biopsy in the supine position in a standard 1.5-T scanner under real time MR-imaging control using a MR-compatible endorectal biopsy device.

Authors:  K Engelhard; H P Hollenbach; B Kiefer; A Winkel; K Goeb; D Engehausen
Journal:  Eur Radiol       Date:  2006-02-01       Impact factor: 5.315

4.  T2-weighted MR imaging of prostate cancer: multishot echo-planar imaging vs fast spin-echo imaging.

Authors:  Tsutomu Tamada; Teruki Sone; Kiyohisa Nagai; Yoshimasa Jo; Masayuki Gyoten; Shigeki Imai; Yasumasa Kajihara; Masao Fukunaga
Journal:  Eur Radiol       Date:  2003-10-18       Impact factor: 5.315

Review 5.  Advances in MR spectroscopy of the prostate.

Authors:  John Kurhanewicz; Daniel B Vigneron
Journal:  Magn Reson Imaging Clin N Am       Date:  2008-11       Impact factor: 2.266

6.  Can prostatic arterial embolisation (PAE) reduce the volume of the peripheral zone? MRI evaluation of zonal anatomy and infarction after PAE.

Authors:  Yen-Ting Lin; Grégory Amouyal; Jean-Michel Correas; Héléna Pereira; Olivier Pellerin; Costantino Del Giudice; Carole Déan; Nicolas Thiounn; Marc Sapoval
Journal:  Eur Radiol       Date:  2016-01-06       Impact factor: 5.315

7.  Radiomic Features of Primary Rectal Cancers on Baseline T2 -Weighted MRI Are Associated With Pathologic Complete Response to Neoadjuvant Chemoradiation: A Multisite Study.

Authors:  Jacob T Antunes; Asya Ofshteyn; Kaustav Bera; Erik Y Wang; Justin T Brady; Joseph E Willis; Kenneth A Friedman; Eric L Marderstein; Matthew F Kalady; Sharon L Stein; Andrei S Purysko; Rajmohan Paspulati; Jayakrishna Gollamudi; Anant Madabhushi; Satish E Viswanath
Journal:  J Magn Reson Imaging       Date:  2020-03-26       Impact factor: 4.813

Review 8.  MRI-targeted prostate biopsy: a review of technique and results.

Authors:  Nicola L Robertson; Mark Emberton; Caroline M Moore
Journal:  Nat Rev Urol       Date:  2013-09-24       Impact factor: 14.432

9.  Evaluation of the Prostate Imaging Reporting and Data System for Magnetic Resonance Imaging Diagnosis of Prostate Cancer in Patients with Prostate-specific Antigen <20 ng/ml.

Authors:  Xuan Wang; Jian-Ye Wang; Chun-Mei Li; Ya-Qun Zhang; Jian-Long Wang; Ben Wan; Wei Zhang; Min Chen; Sa-Ying Li; Gang Wan; Ming Liu
Journal:  Chin Med J (Engl)       Date:  2016-06-20       Impact factor: 2.628

10.  Multiparametric magnetic resonance imaging of prostate cancer.

Authors:  Sandeep S Hedgire; Tamara N Oei; Shaunagh McDermott; Kai Cao; Zena Patel M; Mukesh G Harisinghani
Journal:  Indian J Radiol Imaging       Date:  2012-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.